Solvay Biologicals:
http://www.solvaypharmaceuticals-us.com ... 2-0,00.htm
About Us
Solvay Biologicals, LLC is a wholly-owned subsidiary of Solvay Pharma US Holdings, Inc., the same parent company of Solvay Pharmaceuticals, Inc. Launched in January 2008, the company focuses exclusively on the research and development and ultimately, the manufacturing of the company’s cell-based influenza vaccine in the U.S.
Mission
Solvay Biologicals aims to prevent and protect the American public from the onset and spread of influenza through innovative and pioneering research and manufacturing technology.
Про деятельность компании на гриппозном фронте:
http://www.solvaypharmaceuticals-us.com ... 2-0,00.htm
Про её участие в Грипполе:
http://www.itnews.it/news/2009/09090802 ... ional.html
In parallel, Solvay Pharmaceuticals also announces the registration of the first trivalent adjuvant cell-based
seasonal 
influenza vaccine Grippol® Neo in Russia. This registration is the result of a fruitful and long-standing co-operation with the Russian pharmaceutical company Petrovax (Moscow, Russia), which obtained the required production certificate and registration for the vaccine for Russia. Grippol® Neo is a seasonal influenza vaccine based on
influenza antigens produced by Solvay Biologicals in its cell-based facility and Petrovax's proprietary adjuvant
Polyoxidonium®. This new preservation free vaccine is formulated in a fully ISO and GMP certified facility of Petrovax near Moscow. Grippol® Neo will be marketed in Russia during the upcoming influenza season of 2009/2010. "The validation of our new, state-of-the-art cell-based production plant will further reinforce Solvay Pharmaceuticals' strong position and enable it to contribute even more to the protection of millions patients around the world against the influenza virus," says Drs. Sjirk Kok, Executive Vice-President, Solvay Biologicals. Update on Solvay Pharmaceuticals' pandemic influenza vaccines development (H1N1) The company's egg-based production facility is currently producing seasonal vaccines at full capacity till mid September. When this production is completed, pandemic H1N1 antigens will be produced in the egg-based facility for feasibility studies. Meanwhile, the production of clinical batches of pandemic H1N1 antigens was initiated in the cell-based facility in late August. Further decisions on the development of pandemic influenza vaccines have not been taken at this point and will depend on different factors, including the results from the feasibility studies and future guidelines from health authorities. With this strategy Solvay Pharmaceuticals retains its production capacity to fulfill the global medical need for seasonal influenza vaccines, while being ready to switch production in its egg-facility from seasonal vaccines to pandemic vaccines if the need arises. ... Grippol® Neo belongs to a novel generation of adjuvanted inactivated subunit vaccines and is delivered as single-use syringes. PETROVAX GROUP is a Russian pharmaceutical company that was founded in 1996. Petrovax Group develops and produces a range of innovative pharmaceutical products and vaccines, including the influenza vaccine Grippol®. Solvay Pharmaceuticals and Petrovax collaborate since 2004 on the development of next generation vaccines.
Полиоксидоний на сайте производителя - просто чудо научной мысли:
http://www.polyoxidonium.ru/
повышение исходно сниженных, или понижение исходно повышенных показателей, что делает возможным назначение препарата без предварительного иммунологического исследования
На кого они работают?, если полный текст можно найти только по-английски и на чужих сайтах:
http://www.pharmacy1010.com/product_page.asp?id=1461
...synthetic immunomodulator, which is a water soluble high-molecular compound, an N-oxidized polyethylene-piperazine derivative
...Contraindications and cautions:
Personal intolerance. Pregnancy, lactation (no clinical experience on application). Use with cautions when acute renal insufficiency is registered.
Опасная штука, в онкологии применяется:
http://www.anticancer.net/reviews/
Polyoxidonium is a high-molecular weight physiologically active compound with pronounced immunomodulating activity, an N-oxidized polyethylene–piperazine derivative. The analysis of immunomodulating effect produced by Polyoxidonium proved its stimulating activity on some cytokines production in vitro, e.g. interleukin 1β (IL-1β), tumor necrosis factor (TNF)-α and IL-6. A dose-dependent increase in the intracellular killing by blood phagocytes was established under the action of Polyoxidonium.
